晚期前列腺癌同源重组修复突变的真实世界患病率:两项临床基因组数据库分析
该横断面分析纳入3757例接受二代测序(NGS)作为标准诊疗的前列腺癌个体。CGDB中晚期/转移性前列腺癌的HRRm(胚系和/或体细胞)患病率为24.6%(95%CI 20.9-28.7%),GENIE中体细胞HRRm患病率为11.0%(95%CI 10.0-12.1%),不同治疗中心间为9.5%至18.4%。结论认为CGDB结果与PROfound等临床试验一致,GENIE中HRRm患病率随治疗中心或NGS平台而异,需更多研究理解真实世界HRRm患病率差异。
要点
- CGDB中晚期/转移性前列腺癌HRRm(胚系和/或体细胞)患病率为24.6%(95%CI 20.9-28.7%)。
- GENIE中体细胞HRRm患病率为11.0%(95%CI 10.0-12.1%),不同治疗中心间为9.5%至18.4%。
- CGDB结果与使用类似NGS平台和算法定义HRRm的PROfound等临床试验一致。
核心结论
- CGDB中约四分之一的晚期/转移性前列腺癌患者存在胚系和/或体细胞HRRm,与使用类似NGS平台和算法定义HRRm的PROfound等临床试验一致。
- GENIE数据库中HRRm患病率随治疗中心或NGS平台而异。
- 需更多研究理解真实世界HRRm患病率差异。
研究设计与样本
- 横断面分析,纳入3757例诊断为前列腺癌并以NGS作为标准诊疗的个体。
- CGDB为全国电子健康记录衍生的数据库,纳入晚期/转移性前列腺癌男性,遗传数据包括胚系和体细胞致病突变。
- GENIE分析纳入接受NGS作为标准诊疗的前列腺癌男性,但数据过滤为仅包括体细胞突变。
- 由于数据库间关键差异,无法进行直接比较。
主要发现
- CGDB(n=487)中HRRm(胚系和体细胞合并)患病率为24.6%(95%CI 20.9-28.7%),各人口学和疾病特征亚组间无重大差异。
- GENIE(n=3270)中HRRm(体细胞)患病率为11.0%(95%CI 10.0-12.1%),不同治疗中心间为9.5%至18.4%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Homologous recombination repair mutation (HRRm) status may guide risk-stratification and treatment decisions, including polyadenosine diphosphate-ribose polymerase inhibitor use, in advanced prostate cancer. Although HRRm prevalence has been reported in single-institution studies or clinical trials, real-world HRRm prevalence in diverse populations is unknown. We describe HRRm in the clinical setting using two real-world clinicogenomic databases: the Flatiron Health and Foundation Medicine, Inc. Clinico-Genomic Database (CGDB), a national electronic health record-derived database, and the American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange (GENIE). METHODS: This cross-sectional analysis included 3757 individuals diagnosed with prostate cancer who had next generation sequencing (NGS) as standard of care. The CGDB included men with advanced/metastatic prostate cancer and genetic data included both germline and somatic pathogenic mutations. The GENIE analysis included men with prostate cancer whose received NGS as standard of care, but the data were filtered to include somatic mutations only. Due to key differences among databases, direct comparisons were not possible. Overall prevalence of HRRm was calculated and stratified by demographic and clinical characteristics. RESULTS: HRRm prevalence (combined germline and somatic) in CGDB (n = 487) was 24.6% (95% CI 20.9-28.7%), with no major differences across demographic and disease characteristic subgroups. HRRm prevalence (somatic) in GENIE (n = 3270) was 11.0% (95% CI 10.0-12.1%), which varied between 9.5% and 18.4% across treatment centers. CONCLUSIONS: Approximately one-quarter of patients with advanced/metastatic prostate cancer in the CGDB had germline and/or somatic HRRm, which is consistent with clinical trials such as the PROfound study that used a similar NGS platform and algorithm to define HRRm. In the GENIE database, HRRm prevalence varied by treatment center or NGS platform. More research is needed to understand real-world HRRm prevalence variations.
引用
- Shui IM, Burcu M, Shao C, et al. Real-world prevalence of homologous recombination repair mutations in advanced prostate cancer: an analysis of two clinico-genomic databases. Prostate Cancer Prostatic Dis. 2023. PMID: 38057611. doi:10.1038/s41391-023-00764-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。